LONGBIO-B (01779.HK): BLA of LP-003 for seasonal allergic rhinitis accepted by NMPA

NewTimeSpace News: On 21 August 2026, LongBio Pharma (Suzhou) Co., Ltd. (stock code: 01779) announced in a voluntary announcement that the biologics license application (BLA) of LP-003 for the indication of seasonal allergic rhinitis has been accepted by China's National Medical Products Administration (NMPA).

According to the announcement, LP-003 is an anti-IgE antibody with a novel sequence design, targeting allergic diseases including seasonal allergic rhinitis, chronic spontaneous urticaria (CSU), allergic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and food allergy, with its main function being to block free IgE in the blood and tissues to inhibit IgE-mediated allergic reactions. The Company has obtained IND approvals and/or initiated clinical trials for LP-003 across multiple indications in China, and the IND application of LP-003 for peanut allergy has also been approved by the US FDA. The Company is a clinical-stage biopharmaceutical company founded in 2020, focusing on the discovery and development of biologics for allergic and autoimmune diseases.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.